| Name | Title | Contact Details |
|---|---|---|
Vinay Gidwaney |
Head of Technology | Profile |
Devereux Advanced Behavioral Health is one of the largest and most advanced behavioral healthcare organizations in the country. Informed by the latest advancements in science and medicine, we combine evidence-based interventions with compassionate family engagement to help change lives. We were founded in 1912 by special education pioneer, Helena Devereux. Today, Devereux is a national nonprofit partner for individuals, families, schools and communities, serving many of the most vulnerable members of our society in areas of autism, intellectual and developmental disabilities, specialty mental health, and child welfare. Our Mission: Devereux Advanced Behavioral Health changes lives – by unlocking and nurturing human potential in people living with emotional, behavioral or cognitive differences. Devereux Advanced Behavioral Health employs more than 7,500 staff and operates 15 centers in 13 states. We offer a comprehensive national network of clinical, therapeutic, educational, and employment programs and services that positively impact the lives of tens of thousands of children, adults – and their families – every year. Our Culture, Our Expectations At Devereux, we strive to incorporate servant leadership into our culture and every aspect of our organizational framework; from the delivery of quality services to individuals served, their families, and other stakeholders to the development and empowerment of our employees. We offer challenging and exciting work, and our supportive team environment creates an empowering and positive atmosphere. To be successful in our work environment, you will put the needs of others first, and will feel called to serve, and called to lead.
Sharn Inc is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Prince Agri Products is a Quincy, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
American Standards Testing Bureau is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.